A problem when routinely using PDT has been the difficulty of controlling the light dose in order to expose the tumour to the right amount of light to achieve adequate treatment effect. SpectraCure has developed the IDOSE® dose planning platform for this purpose. SpectraCure’s IDOSE® software has the potential to make interstitial PDT treatment accurate, precise and safe for each patient.

In established prostate cancer care it is normal to attempt to treat the whole gland, even though the cancer tumour itself is only a minor part of the volume. The purpose of this treatment strategy is to avoid missing any part of the cancer tumour. Against this background, SpectraCure’s initial intention of treatment method was to treat the whole prostate gland with the maximum number of needles.
SpectraCure has then further developed the software IDOSE®, which has led to improved precision and the possibility to perform so called focal PDT treatment.

In focal treatment, the focus is only on treating the cancer tumour within the prostate. Focal PDT treatment requires the physician to have information about the location and size of the tumour, which can be given by, for example, MR images.

Focal PDT treatment is mainly relevant for two different categories of prostate cancer patients. One group is patients with primary prostate cancer with low risk of spreading, and the other group is patients treated with radiotherapy but who suffer recurrence.


How it works

Individualised dosimetry

The light dose from each individual optical fibre is monitored in real time so that it can be adjusted during the course of treatment. Therefore, the technology can potentially reduce the risk of incomplete treatment and make the treatment outcome independent of tissue variations.


SpectraCure’s system with IDOSE® provides a targeted treatment since the PDT effect only occurs in the area where the light dose is delivered.


Damage to tissue surrounding the treatment area can potentially be minimised through the SpectraCure IDOSE® system, as it is possible to monitor and adjust the light dose from each individual optical fibre.


Internal tumours can be treated with SpectraCure’s technology without the risks associated with, for example, ionising radiation.

Interview with Dr. Neil Fleshner

On November 21st, 2017, SpectraCure arranged a meeting where, amongst other investigators, Dr. Neil Fleshner participated. Dr. Fleshner is a professor at the Department of Urology at the University of Toronto. He is head of uro-oncology at the Princess Margaret Cancer Centre in Toronto, where the first patients in the company's clinical phase 1 study were treated.

P18 generation 2

Before product launch, SpectraCure’s P18 system will be updated with modern design and improved user interface and ergonomics.

Together with further development of the software IDOSE®, the result will be a next generation of SpectraCure’s system, easier for the hospital staff to work with, and also more adaptable to the patients’ individual needs.